ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma

Launched by SUZHOU ZELGEN BIOPHARMACEUTICALS CO.,LTD · Jun 18, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment that combines two medications, called ZG006 and ZG005, to see if they are safe and helpful for people with advanced small cell lung cancer or neuroendocrine carcinoma, which are types of cancer affecting the lungs and other related tissues. The goal is to find out if this combination can better control the cancer and improve patients’ health.

Adults between 18 and 70 years old who have been diagnosed with these cancers and are in generally good health (able to carry out daily activities without much difficulty) may be eligible to join. Participants need to understand the study and agree to take part by signing a consent form. If accepted, they can expect to receive the study medications under careful medical supervision, with regular check-ups to monitor how well the treatment is working and to watch for any side effects. The trial is currently not recruiting participants yet, but it will involve multiple centers, meaning it will take place at different medical locations.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Fully understand the study and voluntarily sign the informed consent form.
• • Male or female 18-70 years of age.
• • Participants with advanced small cell lung cancer or neuroendocrine carcinoma confirmed by histopathology or cytology.
• • Eastern Cooperative Oncology Group (ECOG) 0 to 1.
• • Life expectancy \> 3 months.
• Exclusion Criteria:
• • The investigator believes that the subject has other reasons that make them unsuitable for participation in this study.